Xarelto: Fake anticoagulants: hypertensive patients can recognize them



[ad_1]

The responsible federal institute is currently warning consumers against the counterfeit drug Xarelto for blood pressure. In the meantime, three affected lots have been discovered and can be recognized by patients using the logo.

As currently reported by the Federal Institute for Drugs and Medical Devices, three lots of counterfeit anticoagulants are in circulation.

What product is it?

Xarelto 20 mg film-coated tablets
Manufacturer of origin: Bayer AG
Active ingredient: rivaroxaban
National presentation: Polish-Slovak

That's what the original medicine looks like in a German package
BfArMThat's what the original medicine looks like in a German package

Which patients are affected?

Xarelto is widely prescribed for the prevention of cerebrovascular accidents and systemic embolism, as well as for the treatment of venous thrombosis and pulmonary embolism.

How can you recognize fake ones?

Designation of the 3 counterfeit lots: BXHVHC3, BXHXL41 and BXHUBD2
Expected date of expiration: 09/2020

Photo of fake (left) and original without stray light (right)
BfArMPhoto of fake (left) and original without stray light (right)
  • On the top of the blisters are printed on counterfeit lots, Bayer logos and always recognizable from all angles. When the original product is used, the Bayer logo is embossed and poorly recognizable by stray light (oblique).
  • For the product of origin, the perforation lines are clearly visible. For counterfeit batches BXHVHC3 and BXHXL41, the two perforation lines are not visible (see photos of 05.06.19). For counterfeit lot BXHUBD2, the punch line is weak.

IM VIDEO: Why Xarelto is so important for Bayer

What does it take now?

BfArM invites parallel distributors, wholesalers, pharmacists and users to check the medicines listed above and report any suspicious cases to BfArM.

The investigations are not yet complete in this case. The origin of the falsification is examined. BfArM maintains close relations with national drug control authorities in Germany and with the European Medicines Agency, EMA. As soon as additional information is available, BfArM will immediately inform.

[ad_2]
Source link